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CLINICAL STUDIES
Anglogenic Effects of 11
Stable Coronary Artery Dise
Objectives . The study was designed to assess the feasibility of
conducting a trial to investigate whether exercise and low molec-
ular weight heparin therapy with dalteparin sodium (Fragnim)
would improve collateral function to the ischemic myocardium in
patients with coronary artery disease .
Background . The severity of myocardial ischemia in patients
with coronary artery disease is at least partly dependent on the
status of the collateral circulation . Therefore, improvement in
collateral function would potentially provide a unique way of
alleviating myocardial ischemia . Because the combination o5'isch-
emin and heparin has previously been demonstrated to enhance
collateral growth, we studied the anti-ischemic effects of combined
treatment with dafteparin sodium and exercise-induced ischemin
in patients with coronary artery disease .
Alethods . Twenty-three patients with stable coronary artery
disease were randomized to receive either subcutaneous dalle-
parin sodium or placebo for a 4week period . Patients received
either placebo or 10,0W lU of dalteparin sodium by subcutaneous
injection once daily for weeks I and 2 and 5,000 1U daily for weeks
3 and 4. During the 1st 2 weeks, patients were exercised to
ischemia three times a day . At baseline and 4 weeks after
treatment, treadmill exercise testing, exercise radionuclide ven-
triculography nd 40-h ambulatory ST segment monitoring were
pedrawd.
Myocardial ischemia is often inadequately relieved by con-
ventional t%erapy in patients with coronary artery disease .
Because the magnitude of myocardial ischemia is related to
oxygen demand, the severity of the coronary stenoses and
status of the collateral circulation subserving the ischemic
myocardium, it is likely that enhancement of collateral
function not only would potentially provide a unique way of
relieving myocardial ischemia and ameliorating symptoms,
but also would reduce the size of the myocardial infarct zone
if infarction occurred as a result of sudden occlusion of the
feeder artery .
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Results. Eight (80%) of the 10 dalteparin sudium4reated
patients compared with 4 (31%) of 13 placebo-treated patients
(p < 0.02) had an increased rate-pressure product at the onset of
1
mm of ST segment depression. The duration of exercise to
ischemia increased in all patients treated with low molecular
weight heparin and in 62% of placebo-treated patients (p < 0 .03) .
The number and duration of episodes of ST segment depression
during ambulatory monitoring decreased by 30% and 35%,
respectively (p < 0 .05), in the dalteparin sodium group but were
unchanged in the placebo group. The decrease in left ventricular
ejection fraction with exercise was lower in 80% of dalteparin
sodium-treated patients compared with 54% of placebo-treated
patients (p = 0 .06), When all five factors reflecting collateral
function were considered together in a multivariate analysis of
variance, there was a significant improvement in low molecular
weight heparin-treated patients compared with placebo-treated
patients (p = 0 .014) .
Conclusions . This study provides preliminary evidence sug-
geAng that exercise and low molecular weight heparin therapy
with dalteparin sodium lessen myocardial ischemia and that the
improvement is likely to be mediated by enhanced collateral
function .
(J App;
roll
Cardiol 1993,22:635-41)
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Sustained ischemia stimulates collateral growth (1-8),
which is at least partly due to local release of growth factors
(5) . Heparin potentiates the activity of growth factors
(9-11),
and the combination of heparin and ischemia has been
demonstrated in canine models and humans to enhance
collateral function and growth (12-14)
Low molecular weight, nonanticoagulant fragments of
heparin also possess angiogenic properties . Dalteparin so-
dium (Fragmin) (Kabi Pharmacia AB, Stockholm, Sweden),
a low molecular weight heparin fragment, has higher bio-
availability, a longer half-life and less risk of bleeding than
standard heparin (15-22)
. We undertook the present pilot
investigation to determine the feasibility and potential effi-
cacy of a trial of a combination of subcutaneous dalteparin
sodium- and exercise-induced iwhewo4a
in producing a clin-
ically important improvement ir, collateral function in pa-
tients wit i stable coronary artery disease
. An increase in the
rate-pressure product tad the duration of exercise at the
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*p < 0 .05 . Unless otherwise indicated, data are expressed as number
of patients . NYHA = New York Heart Association .
onset of myocardial ischemia, a reduction in the number and
duration of episodes of myocardial ischemia during daily
activities and an improvement in left ventricular function
with exercise were prospectively used as indirect indexes of
improved collateral function to the ischemic myocardium .
Methods
Patients . Twenty-three patients with stable coronary ar-
tery disease, defined as >70% stenosis in one or more major
epicardial coronary arteries and evidence of inducible isch-
emia on exercise testing . were recruited for this study (Table
1). Patients were randomized in a double-blind manner into
two groups that received either dalteparin sodium or pla-
cebo. Because of the possible variation in the potential for
collateral development in different subsets, we stratified
patients before randomization into three groups : 1) patients
with three-vessel disease, 2) patients who had had coronary
artery bypass graft surgery, and 3) the remaining patients
without previous bypass surgery and at least one major
unobstructed coronary artery. The study was continued until
a 10 patients had been randomized into the two treatment
groups . At the end of the investigation, 10 patients were
randomized to receive dalteparin sodium and 13 received
placebo.
After written informed consent was obtained, all antiangi-
nal medications were discontinued for ?72 hours before the
study period. One patient had a long-standing history of
hypertension and was maintained on enalapril therapy
throughout the study period
. The study was approved by the
JACC Vol. 22, No. 3
review body of the National Heart, Lung, and Blood Insti-
tute .
Treadmill exercise and drug treatment . At the initial
evaluation, patients underwent two maximal treadmill exer-
cise tests between 8 AM and 2 PM . The protocol was selected
so that exercise duration before onset of significant (I mm)
ST segment depression was between 4 and 10 min . Nineteen
patients exercised using the Bruce protocol and four patients
using the combined National Institutes of Health protocol
(23) . An intra-arterial indwelling catheter was placed in the
brachial artery to allow continuous blood pressure measure-
ment and an electrocardiogram was recorded every 30 s
during the treadmill test so that an accurate rate-pressure
product could be obtained at specified end points .
Patients were randomized to receive either placebo or
dalteparin sodium therapy for a 4-week period. They were
hospitalized during weeks I and 2 and received either
placebo or 10,M IU of dalteparin sodium at 7 AM each
morning by subcutaneous injection . After .30 min, all
patients underwent three treadmill exercise training periods
that were completed within 8 h of the injection . The protocol
was individualized so that once I mm of ST segment
depression developed, the speed and angle of the treadmill
were kept constant and patients continued to exercise at the
same work load for an additional 5 min . Exercise was
terminated at the development of moderately severe chest
pain, fatigue, or 10 min after development of 1-mm ST
segment depression. This protocol provided three periods/
day of sustained myocardial ischemia .
Patients were discharged during weeks 3 and 4, when
they self-administered dalteparin sodium or placebo (5,000
IU subcutaneously/day) . All patients were sent home with-
out antianginal medications ; nitroglycerin was available for
pain but not for prophylactic use . After the 2-week outpa-
tient period, patients were readmitted and underwent repeat
exercise testing .
The following measurements were made during treadmill
exercise testing before and after the 4-week treatment pe-
riod : the rate-pressure product and duration of exercise at
1) the onset of I mm of ST segment depression, 2) the onset
of chest pain, and 3) the end of exercise . Mean values from
the two testing periods are reported .
Radionuclide ventriculography . Gated equilibrium radio-
nuclide cineangiography was performed at rest and during
maximal symptom-limited bicycle exercise at baseline and
repeated after 4 weeks at the same peak exercise work load .
The left ventricular ejection fraction was determined by
computer analysis of the scintigraphic data and regional left
ventricular function was assessed subjectively as previously
described (21,24). The lower limit for normal rest ejection
fraction in our laboratory is 45% .
Ambulatory ST segment monitoring . Before and at the
end of the 4-week treatment period, patients underwent
ambulatory ST segment monitoring for 48 h during unre-
stricted normal daily activities out of the hospital and were
asked to keep a detailed diary of their symptoms . Bipolar
Table 1. Patient Characteristics
Dalteparin Sodium
(n = 10)
Placebo
(n = 13)
Male 10 12
Mean age (yr ; range) 66,58-72 60
; 50-66*
Mean cholesterol (mg/dl ; range) 242 ; 162-268 235
;147-324
Hypertension 6 (60)
5(38)
NYHA functional class
1 2 OW 3 at
it
8(80) 10(77)
Coronary bypass surgery 2(20) 4(31)
Myocardial infarction 1(10) 5(38)
Patients with left ventricular 3(30) 4(31)
ejection fraction <45%
Previous drug therapy
Rcta .blockers 7(70) 6(46)
Calcium antagonists 6 (60) 10(77)
Nitrates 2(20) 5 (38)
Aspirin 9 (90) 13(100)
Coronary artery disease
I-vessel 6 (60) 6(46)
2wessel 3 (30) 5 (38)
3-vessel 1(10) 2(15)
Collateral vessels present 5(50) 9 (69)
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CM5 leads and modified lead 11 were monitored and the tapes
were analyzed visually at 120 times normal speed, employing
the Delmar Avionics model 750A system as previously
described (23,25). An ischemic episode was defined as
~ 1 mm of ST segment depression that occurred 0.08 s after
the J point and was either planar or downslcping and lasted
>_l min. Return of the ST segment to baseline for Q min
was required between two episodes .
Coagulation measurements . There were no bleeding com-
plications . Partial thromboplastin time increased from
29.2 ± 1 .7 s at baseline to 38 .2 ± 4.2 s after 4 h and was
29.8 ± 2 .2 s at 24 h . Antifactor Xa activity was 0 .65 ±
0.1 IU/ml 4 h after and 0.26 ± 0.05 IU/ml 24 h after
subcutaneous dalteparin sodium injection .
Statistical
analysis. The treatment versus control compar-
isons for change in continuous variables were assessed
parametrically using the Student t test and nonparametri-
cally using a comparison of the proportions improving during
the course of the trial (follow-up minus baseline values). The
comparison of proportions was made using a chi-square
statistic . Among the comparisons, the rate-pressure product
at 1-mm ST segment depression was deemed before testing
to be the single most important determinant of ii provement
in collateral function . Because the treatment was exptcted
to improve several variables, we performed a multivariate
nonparametric analysis, assessing the combined change of a
cluster of five variables selected before the study because of
their importance as determinants of a change in collateral
function. These included : 1) the ivt?-pressure product at
1-mm ST segment depression during treadmill exercise, 2)
the duration of exercise to I mm of ST segment depressicri,
3) the number of episodes of ST segment depression during
QUYYUMI ET AL .
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Table 2. Results of Treadmill Exercise, Ambulatory ST Segment Monitoring and
Radionuclide Ventriculography
*p < &M, ip ,
0 .05 . Values arc cipmW m mea"alm ± SD or number (%) of p atients . L V -- left ventricular
RPP = rate-pressure product .
ambulatory monitoring, 4) the duration of episodes during
monitoring, and 5) the change in left ventricular ejection
fraction with exercise . The multivariate nonparametric anal-
ysis was based on the improvements in each of the five
selected variables taken together . These five binomially
distributed variables were analyzed using a multivariate
analysis of variance. Because the binomial distribution is
symmetric and approximated by a normal distribution, a
standard statistical multivariate analysis of variance package
(SAS Statistical computer package 6 .0, SAS lnstitu'-,) was
used. A p value s 0 .05 was considered significant . Results
are expressed as mean value ± SD .
Results
Patient characteristics (Tables 1 and 2). Baseline charac-
teristics, left ventricular function and angiographic severity
of disease were similar in the two groups, except that
patients rneiving dalteparin sodium were on average 6 years
older than those in the placebo group .
Treadmill exercise testing (Table 2, Fig. 1 to 3)
. Eight
(80%) of the 10 dalteparin sodium-treated and 4 (31%) of the
13 placebo-treated patients had an increase in rate-pressure
product at 1-mm ST segment depression (p = 0 .019) (Fig. 1~ .
The responses were heterogeneous in both groups, such that
there was no significant change in the mean magnitude of
increase in rate-pressure product at 1-mm ST segment de-
pression either in the low molecular weight heparin- or
placebo-treated groups (Table 2, Fig . 2) .
All low molecular weight heparin-treated patients in-
creased the duration of exercise to the development of
ischemia, compared with 8 (62%) of 13 placebo-treated
Balleparin Sodium Group
Placebo Group
Baseline 4 Weeks
Basel ne 4'%Vn:kS
Treadmill exercise
Rest RPP (beats/min-mm Hg-10 - ')
11 .9 ± 2 .4
11
.8 ± 2 .3 11 .6 ± 2
11 .1 ± 2 .7
RPP at I mm ST depression 24 .5± 7 .1 24.6±4.8 23
.2 ± 6.4 23 .4 ± 6 .5
Duration to I mm ST depression (min) 5.6±-
2 .6
7.6±2
.2* 6.5 ± 3
B ± 3 .7t
Patients with chest pain 7 (70) 6 (60)
9 (69) 8 (62)
RPP at chest pain (beats/min-mm Hg' l0 - ') 23.7±5.7 DO 31 22 .6 ± 5
22 .5 ± 5 .6
Duration to chest pain (min)
5.4±3.2
7 .7 4 .Of 5 .9 ± 2 .1 7.1 ± 2 .9
RPPaA end test (beats/min-mm ilg . 10 -1) 27.6±5.8 29.1±4.4 27 .2 ± 7 .1
28 .7 ± 7 .1
Duration at end test (min) 7.5±2.6 10 .8±'3 .3* 9 .3 ± 2 .5 11 .2 ± 3 .8*
Ambulatory ST segment monitoring
Mean number of episodes/IN h 3.23 2 .2±2 .3 5.3±4.7
5
.4±4
.6
Mean duration of episodes148 h (min)
112 ± 105 73 ± 981
171 ± 01 240 ± 299
Radionuclide ventriculography
Rest LV ejection fraction (%) 51 ± 7 .8 46 t 5 49 ± 9.1
49 ± 9
Exercise LV ejection fraction (%) 43±10 48a10 47±- 6 .3 49±- 10
Change in LV ejection fraction
m2 . 5 a_4.2
1±6
.6
-1 .2 -!6.7 --0.2±7.7
Exercise heart rate (beats/rain) 105 ± 17 107 ± 13 109 ± 17 109 ± 19
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Figure 1
. Percent of patients in the dalteparin sodium (black bars)
and placebo (gray bars)
groups who demonstrated improvement
after I month of therapy in 1)
rate-pressure product (RPP) at the
onset of 1 mm of ST segment depression during treadmill exercise,
2) duration of exercise to the onset of I
mm of ST segment
depression, 3) number, and 4) duration of episodes of ST sogirrem
depression during ambulatory monitoring, and
5) change in left
ventricular ejection fraction (AEF) with exercise . Multivariate
analysis of valiance using these variables demonstrated a significant
difference in the dalteparin sodium group compared with the placebo
group (p - 0,014) . *p < 0
.03 .
patients (p = 0
.023) (Fig . I and 3) . The magnitude of increase
in duration of exercise was 2 ± 1
.5 min (36%, p < 0.003) in
the treated group and 1 .5 ± 1 .8 min (23%, p < 0.03) in the
placebo group (Table 2) .
Five (83%) of the six treated patients and three (38%) of
the eight placebo group had an increase in the rate-pressure
product at the onset of chest pain (p w NS). The duration of
exercise to chest pain increased by 42% in the treated
Figure 2. Rate-pressure product at the onset of t mm of ST segment
depression during exercise in the dalteparin sodium (Fragmin) and
placebo groups at baseline and at 4 weeks
. BPM = beats per minute .
S 5
15
1000 1
Fragmin
r--PCa003-7
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Figure 3 . Duration of exercise at the onset of I min of ST segment
depression (STD) in the dalteparin sodium and placebo groups
at
baseline and at 4 weeks .
patients (p = 0 .01), but the change was insignificant in the
placebo group (Table 2) .
The rate-pressure product at peak exercise increased in
80% of the dalteparin sodium-treated patients and in 69% of
the placebo-treated patients (p = NS) . There was a greater
increase in the duration to peak exercise in the dalteparin
sodium-treated patients than in the placebo group (44% vs .
20%, respectively, p < 0.03) (Table 2) .
Ambulatory ST segment monitoring (Table 2, Fig. 4) .
Baseline .
Nine of the 10 low molecular weight heparin-
treated patients and I I of
the 13 placebo-treated patients had
one or more episodes of ST segment depression during 48-h
ambulatory ST segment monitoring. Thirty episodes (70%
silent) lasting 1,064 min were recorded in the dalteparin
Figure 4. Duration of episodes of ST segment depression recorded
during ambulatory ST segment monitoring in the dalteparin sodium
(Fragmin) and placebo groups at baseline and at 4 weeks
.
Fragmin
7-
PA05--
l
Placebo
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sodium group and 69 episodes (85% silent) lasting 2,217 min
were recorded in the placebo group (p = NS) .
After trearment,
The duration of episodes of ST segment
depression was 35% lower in low molecular weight heparin-
treated than in placebo-treated patients after 4 weeks (p <
0
.05), with eight of nine patients developing less ischemia
(Fig. I and 4)
. In contrast, the duration of ischemia was not
significantly changed (40% increase) in the placebo group,
with only 4 (36%) of I I patients experiencing less ischemia
.
Although the number of episodes was also reduced by 30%
in the treated group, in contrast to a 2% increase in the
placebo group, this difference did not achieve statistical
significance (Table 2)
.
Radionuclide ventriculography (Table 2). There was no
change in left ventricular ejection fraction at rest during the
study period in either group
. A decrease (2 .5 m 12%) in left
ventricular ejection fraction with exercise at baseline was
converted to a mean increase after 4 weeks of dalteparin
sodium therapy (p = 0 .09). The change in ejection fraction
with exercise in the placebo group was not significant (Table
2). Eight (80%) of the 10 treated patients compared with 7
(54%) of 13 in the placebo group had less left ventricular
dysfunction with exercise (p = 0
.06) (Fig. 1). The peak
exercise heart rate was not significantly different before and
after I month of therapy (Table 2) .
Multivariate analysis of variance (Fig . 1) . A multivariate
nonparametric analysis of variance was performed using five
variables that were selected in advance because they are
important determinants of collateral function (Fig
. 1) . Thus,
when the change in the rate-pressure product and duration of
exercise at 1 mm of ST depression, in the number and
duration of ischemic episodes during ambulatory monitoring
and in left ventricular ejection fraction with exercise after I
month therapy were compared, there was a significant
improvement in the low molecular weight heparin-treated
compared with placebo-treated patients (p = 0 .014) .
Discussion
Rationale for use of heparin compounds. Both acidic and
basic fibroblast growth factors stimulate endothelial and
smooth muscle cell proliferation and migration in vitro, two
processes that are central to angiogenesis (9-11,26,27) .
Heparin potentiates the proliferative effects of these growth
factors on endothelial cells and has been found to enhance
collateral function in canine models of myocardial ischemia
(12,13) . Of note, it has recently been demonstrated that
recombinant basic fibroblast growth factor enhances collat-
eral function by >40% in dogs (28) .
Low molecular weight heparin . Dalteparin sodium (Frag-
min), a fragment of heparin with a molecular weight of
approximately 5,000 daltons, has several potential advan-
tages over heparin (16-22)
. I) It has 90% bioavailability after
subcutaneous injection, which therefore avoids intravenous
administration . 2) Its 4-h half-life is considerably longer than
that of conventional heparin . 3) It has minimal antithrombin
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activity and its anticoagulant effects are attributable largely
to its antifactor Xa activity
. 4) In postoperative patients,
dalteparin sodium causes less bleeding than does conven-
tional heparin
. With these potential benefit
. over conven-
tional heparin, the question arose as to whether a similar
potentiation of collateral function could be achieved with
low molecular weight heparin fragments as had been
achieved with heparin .
The present investigation is the first double-blind, placebo-
controlled study assessing the effects of ischernia and hepa-
rin compounds in patients with stable coronary artery dis-
ease
. The study was designed as a pilot investigation to
determine the feasibility of conducting such a study and to
help design a large scale study to assess efficacy
. We studied
several indirect measures of collateral function
. 'The rate-
pressure product at the onset of ischemia (I-mm ST segment
depression) was used as evidence of the maximal capacity of
the coronary circulation to supply oxygen to the myocar-
dium. Other less specific indexes of collateral function that
were measured included the duration of exercise to isch-
emia, magnitude of ischemia during daily living (using am-
bulatory ST segment monitoring) and the degree of left
ventricular dysfunction with exercise .
Although the results cannot be considered conclusive, the
data suggest a beneficial effect of low molecular weight
heparin on collateral function (Fig . 1)
. Compared with the
placebo group, significantly more patients who received the
low molecular weight heparin had improved combined in-
dexes of collateral function
. Thus, in the 80% of the treated
patients who demonstrated less exercise-induced ischemia,
there was an 8
.5% increase in the rate-pressure product and
a 54% increase in exercise duration to ischemia . Addition-
ally, there was a 35% reduction in the ischemia experienced
during daily life and an improvement of left ventricular
dysfunction induced by exercise in 80% of patients treated
with the low molecular weight heparin (Fig. 1)
. When all five
factors reflecting collateral function were considered to-
gether in a multivariate analysis of variance, there was a
significant improvement in low molecular weight heparin-
treated compared %ith placebo-treated patients (p = 0 .014) .
These results are in concordance with a nonrandomized
study (14) using heparin and exercise ; the magnitude of
improvement in the rate-pressure product we observed was
similar to that reported in that study, :. ,hich also demon-
strated an increased angiographic collateral score
. The im-
proved collateral function implied by our findings could be
due to either an increase in collateral growth or an opening of
preformed collateral vessels . Although an improvement in
these exercise indexes is in keeping with improvement in
collateral function, it may also be due to other as yet
unknown effects of low molecular weight heparin on myo-
cardial oxygen demand or to its tnrombolytic properties,
which may lead to improvement
;n coronary blood flow
during exercise by reducing lesion severity .
Limitations of the study
. Patients with coronary artery
disease often experience a training effect with regular exer-
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cise, and the possibility must always be considered that
collateral function may be stimulated by exercise alone
(29-35) . In fact, the placebo group demonstrated a signifi-
cant training effect as evidenced by an increase in the
duration of exercise to ST segment depression and to peak
exercise; however, there was no increase in the rate-
pressure product at these times .
The severity of the stenosis, the patency of the feeder
vessels that are potential sources of collateral development
and the magnitude and duration of the ischemic stimulus are
all among the more important determinants of collateral
development (6,8,36) . Thus, significant collateral growth is
unlikely to occur in vessels that are AM% narrowed, if there
is significant narrowing in all feeder vessels, or if the
duration of ischemia is limited . To avoid these potential
confounding effects, we 1) selected patients with objective
evidence of myocardial ischemia so that there would be t
good potential for collateral growth, 2) randomized patienti
with three-vessel disease and previous coronary bypass
surgery separately because these groups may have had a
variable and perhaps reduced potential for collateral d --vel-
opment compared with that of other patients, and 3) at-
tempted to standardize the ischemic stimulus during the 1st
2 weeks of treatment ,y exercising patients to ischemia Lhrec
times a day . Despite these measures, it is clear that not all
patients in the low molecular weight heparin roup ri-,-
sponded similarly. Because of the small number sf patients
studied, stratification into subgroups cannot be performed
and our results therefore need to be confirmed by a larger
randomized study .
The conclusion that an increase in rate-pressure product
at the onset of I mm of ST depression during exercise
indicates improved collateral function is based on the as-
sumptions that the rate-pressure product is an indirect
measure of myocardial oxygen demand and that collateral
flow is maximal at the development of ischom
I
ia. However,
other determinants of myocardial oxygen demand, such as
wall stress and contractility, were not measured . Neverthe-
less, the higher rate-pressure product reached in 80% of
dalteparin sodium-treated patients after a longer period of
exercise time than that in the placebo group makes it
unlikely that this higher rate-pressure product was being
offset by a simultaneous reduction in contractility and wall
stress .
Conclusions .
The findings from this pilot study provide
preliminary evidence suggesting that exercise and low
mo-
lecular weight heparin therapy with dalteparin sodium de-
crease myocardial ischernia in patients with stable coronary
artery
disease and that the decrease is likely to be mediated
by enhanced collateral function . Whether a longer duration
of therapy, a higher dose of drug or more exercise training
would have achieved an increased angiogenic response and
whether the observed
;m.provement will persist over time
aced to be investigated further in a long-term trial .
We are grateful to Ann Cropp, PhD, Timothy S
. Callahan and the nurses and
technicians of the National Institutes of Health exercise laboratory for their
assistance.
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